Latest Biotech Sector News

PYC Therapeutics has gained Orphan Drug Designation from the European Medicines Agency for its VP-001 candidate targeting Retinitis Pigmentosa type 11, enhancing its regulatory and commercial pathway in Europe.

Cambium Bio has secured FDA confirmation that a single pivotal Phase 3 trial plus confirmatory evidence will suffice for Biologics License Application submission for Elate Ocular, significantly reducing development expenses and accelerating the pathway to market.

BluGlass has secured an upsized A$8 million placement, including a A$2.3 million cornerstone investment from its board and management, to accelerate its gallium nitride laser manufacturing and support a growing project pipeline.

Racura Oncology has enrolled the first patient in its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib to tackle resistance in EGFR-mutant non-small cell lung cancer. This milestone sets the stage for a multi-centre study aiming to improve treatment outcomes.

Immutep Limited has voluntarily suspended trading of its shares on the ASX pending the release of a key announcement regarding the interim futility analysis of its TACTI-004 Phase III trial. The suspension underscores the market’s anticipation of potentially pivotal clinical trial results.

Paradigm Biopharmaceuticals reports a sharp rise in half-year losses as it intensifies investment in its pivotal Phase 3 trial for knee osteoarthritis, setting sights on a critical interim analysis in mid-2026. The company also expands its osteoarthritis pipeline and maintains strong funding amid a strengthening biotech sector.

Mesoblast Limited is set to release its half-year financial results and operational update, spotlighting its FDA-approved cell therapy and expanding international partnerships.

Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.

BluGlass Limited has extended its contract with the U.S. Department of War by A$1.05 million and appointed a refreshed Board to accelerate its commercial growth in visible laser technology. The company is advancing its GaN laser portfolio amid a US$100 million project pipeline and ongoing R&D investments.

ASF Group Limited closed December 2025 with $1.91 million in cash and nearly four quarters of funding runway, while progressing key investments in mining, technology, and biotech sectors.

Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.

Patrys Limited has completed its acquisition of Reliis Pty Ltd, adding a promising injectable quetiapine program to its clinical pipeline and strengthening its board with two new directors.